Mesothelioma Lawyer: Fwd: Efficacy and safety of pemetrexed in elderly cancer patients: Results of an integrated analysis.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 25, 2008 at 2:49 PM
Subject: Efficacy and safety of pemetrexed in elderly cancer patients: Results of an integrated analysis.
To: mesothelioma77@gmail.com

[1]Crit Rev Oncol Hematol. 2008 Mar 19;
Kulkarni PM, Chen R, Anand T, Monberg MJ, Obasaju CK

PURPOSE: To analyze pemetrexed in elderly patients (>/=65 years) based on data collected in three randomized, phase III registration trials. METHODS: Patients who received pemetrexed as monotherapy or in combination with another drug were included in this analysis (N=764). In all studies, pemetrexed 500mg/m(2) was administered every 21 days. Data from patients receiving pemetrexed were stratified by age +/-65 years. RESULTS: Out of the 764 patients randomized, 271 were >/=65 years of age (35.4%). Of these, 28% had non-small cell lung cancer, 41% pancreatic cancer, and 31% had malignant pleural mesothelioma that was either locally advanced or metastatic. The overall response rate of the integrated database of elderly patients was 21.4%, with complete response in three patients (1.11% in >/=65 years vs. 1.01% in

___
Source: http://www.hubmed.org/display.cgi?uids=18358737
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

Financial Wealth Sites:

Wellness With Wealth.Your Financial Wellness Info

Sitemap

Managing Your Debts

Debts and Loan Consolidation

Debt Consolidation Loan

College Consolidation Loans

Private Student Loans: A Parent's Best Choice?

Consolidate Debt Loans: To Eliminate Credit Card Debts

Consolidate Debt Loans

Consolidate Debt Loans For Your School Debts

School Consolidation Loan Guide